Our research focus

Product pipeline

Phase 1

Phase 2

Phase 3



IgG Next Generation (BT595) - Primary Immune Deficiency (PID)
IgG Next Generation (BT595) - Idiopathic Thrombocytopenic Purpura (ITP)
Fibrinogen (BT524) - Congenital fibrinogen deficiency
Fibrinogen (BT524) - Acquired fibrinogen deficiency
Trimodulin (BT588) - Severe community acquired pneumonia
(BT-063) - Systemic lupus erythematosus
Indatuximab Ravtansine (BT-062) - Multiple myeloma
Indatuximab Ravtansine* (BT-062) - Solid tumors


Overview of all projects and their status from the therapy areas Haematology, Immunology and Intensive care medicine

Further information